Correlation Analysis
Alnylam Pharmaceuticals, Inc. vs Eli Lilly & Co.
ALNY vs LLY
+0.647
Moderate positive
When one moves up, the other tends to follow.
Alnylam Pharmaceuticals, Inc.
↗ALNY
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Market cap 43.8B · 2,500 employees
Eli Lilly & Co.
↗LLY
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Market cap 828.2B · 50,000 employees
Time Series
Relative Performance
Who Moves First
in sync
ALNY and LLY tend to move at the same time.
After testing 13 timing shifts, the strongest relationship was +0.647 (they moved in the same direction).
Do They Crash Together?
Correlation by Market Regime
How these series behave when markets are rising, falling, or diverging. A correlation that holds in drawdowns is very different from one that only works in rallies.
Both Rising
+0.241
13 periods · Return correlation when both series rose
Both Falling
-0.098
6 periods · Return correlation when both series fell
Diverging
-0.464
16 periods · Return correlation when series moved apart
R-Squared
41.9%
Share of variance in one series explained by the other.
Trend Agreement
57.1%
How often both series moved in the same direction period-to-period.
Overlap Quality
1,253
Deep shared window — 1,253 usable pairs.
Significance
p < 0.001
95% CI: [0.614, 0.679]
Scatter
XY Regression
Pipeline
Data quality details
Pipeline
Data quality details
Pipeline Summary
1,253 paired data points survived the daily window.
Raw input
1,253
1,254
Normalized
1,253
1,254
Prepared
1,253
1,254
Aligned
1,253
1,253
Invalid removed
0
A: 0 / B: 0
Duplicates removed
0
A: 0 / B: 0
Alignment drops
1
A: 0 / B: 1
Series A
Alnylam Pharmaceuticals, Inc.
ALNY
Market cap 43.8B · 2,500 employees
Stock · 1,253 raw → 1,253 prepared
Series B
Eli Lilly & Co.
LLY
Market cap 828.2B · 50,000 employees
Stock · 1,254 raw → 1,254 prepared
Sign agreement
100.0%
How often both values share the same sign.
Zero crossings
7
Estimated crossover points between normalized spreads.
Slope
2.0492
Linear regression slope.
Intercept
100.2344
Linear regression intercept.
Related Extremes
Highest and Lowest Correlated
ALNY
Alnylam Pharmaceuticals, Inc.
Highest
+0.842
JPMorgan Chase & Co.
JPM · 1,253 data points
Lowest
+0.460
Johnson & Johnson
JNJ · 1,253 data points
Saved 6 hours ago · ID: stock-alny-vs-stock-lly-daily